New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.
Katleen JanssensChinouk LambrechtsBarbara GeerinckxKen Op de BeeckGuy Van CampHelena OliveresHans PrenenTimon VandammeMarc PeetersPublished in: Current treatment options in oncology (2023)
inhibitors) have shown promising results in clinical trials, as monotherapy or in combination regimens. Although resistance remains an important issue, more knowledge on adaptive resistance and feedback loops in the RAS-pathway has led to strategical combination regimens to overcome this problem. In the past year, many encouraging results have been published or presented at conferences. Even though some of the data is still preliminary, these studies may bring practice-changing results and can lead to a clinical benefit for patients over the coming years. Because of these recent developments, the treatment of RAS-mutated mCRC has become a topic of great interest. Therefore, in this review, we will summarize the standard of care and discuss the most important emerging therapies for this patient population.
Keyphrases
- wild type
- healthcare
- metastatic colorectal cancer
- end stage renal disease
- clinical trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- primary care
- palliative care
- prognostic factors
- quality improvement
- combination therapy
- randomized controlled trial
- electronic health record
- open label
- chronic pain
- affordable care act
- patient reported outcomes
- phase ii
- health insurance